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Background: Several studies demonstrate the role of adipose mesenchymal stem cells (ASCs) in angiogenesis. The
angiogenic mechanism has been ascribed to paracrine factors since these cells secrete a plenty of signal molecules
and growth factors. Recently it has been suggested that besides soluble factors, extracellular vesicles (EVs) that
include exosomes and microvesicles may play a major role in cell-to-cell communication. It has been shown that
EVs are implicated in the angiogenic process.
Results: Herein we studied whether EVs released by ASCs may mediate the angiogenic activity of these cells. Our
results demonstrated that ASC-derived EVs induced in vitro vessel-like structure formation by human microvascular
endothelial cells (HMEC). EV-stimulated HMEC when injected subcutaneously within Matrigel in SCID mice formed
vessels. Treatment of ASCs with platelet-derived growth factor (PDGF) stimulated the secretion of EVs, changed their
protein composition and enhanced the angiogenic potential. At variance of EVs released in basal conditions,
PDGF-EVs carried c-kit and SCF that played a role in angiogenesis as specific blocking antibodies inhibited in vitro
vessel-like structure formation. The enhanced content of matrix metalloproteinases in PDGF-EVs may also account
for their angiogenic activity.
Conclusions: Our findings indicate that EVs released by ASCs may contribute to the ASC-induced angiogenesis and
suggest that PDGF may trigger the release of EVs with an enhanced angiogenic potential.
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Almost all cell types release vesicles which include exo-
somes and microvesicles [1-3]. Due to their heterogeneity
it has been suggested to call them collectively extracellular
vesicles (EVs). EVs participate in cell-to-cell communi-
cation by transfer from one cell to another proteins,
bioactive lipids and nucleic acids [4,5]. EVs produced by
stem cells may deliver to target cells critical information
for tissue regeneration after injury. The adipose-derived
stem cells (ASCs) are candidates for therapeutic appli-
cation as autologous cells can be easily obtained by* Correspondence: giovanni.camussi@unito.it
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unless otherwise stated.liposuction and expanded in vitro. Several beneficial
effects of ASCs have been described including their
ability to stimulate angiogenesis [6], nerve growth [7]
and wound healing [8,9]. Recent studies indicate that
ASC's regenerative actions depend on paracrine mecha-
nisms. ASC conditioned medium contains several
growth factors including vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF)
and may mimic the beneficial effects of cells [10,11].
We previously found that EVs released from stem/pro-
genitor cells may, at least in part, account for the effect
of conditioned medium [12]. EVs derived from endothe-
lial progenitor cells were shown to activate an angio-
genic program in quiescent endothelial cells [13].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the selective expansion and recruitment of undifferenti-
ated mesenchymal cells [14-16], thus favoring wound
healing and vessel formation [17-19]. PDGF induces the
migration and proliferation of mural progenitor cells
during vascular development [14], stimulate endothelial
cells [17] and induces mesenchymal cell transdifferentia-
tion into vessel cells [20,21].
The aim of the present study was to evaluate whether
EVs derived from ASCs in basal condition (b-EVs) and
after PDGF stimulation (PDGF-EVs) were able to promote
angiogenesis. For these purposes, we purified EVs from
non-stimulated and PDGF-stimulated ASCs and charac-
terized their phenotype and protein content. Moreover, we
evaluated the in vitro and in vivo angiogenic potential of
b-EVs and PDGF-EVs.Figure 1 Characterization of ASC-derived EVs subpopulations, collect
representative images of 10k, 100k, and total 100k fractions of b-EVs and PD
different growth factors. Calculations of EVs were performed after ultracent
pretreated with blocking antibodies anti PDGFRα/β and then stimulated w
of concentration of EV 10k, 100k g and 100k total fractions in conditioned
western blot analysis of exosome marker expression in the two fractions of
staining in Additional file 1: Figure S1A); E: diagram of length of vessel-like
non-stimulated HMEC were used (mean ± SEM, * - p < 0,05, n = 5).Results and discussion
Characterization of ASC-derived EVs
EVs were collected from ASC conditioned medium in basal
condition and after stimulation with 20 ng/ml PDGF, FGF
or VEGF. The conditioned medium was submitted to
differential ultracentrifugation. After removal of cell debris
and apoptotic bodies at 3k g the fraction obtained by
ultracentrifugation at 10k and 100k g were analysed by
NanoSight, showing similar mean size (250 ± 36 nm and
232 ± 49 nm, respectively). There was a difference between
mode size of vesicles in basal conditions and after PDGF
stimulation. In basal conditions mode size was unique and
equal to mean size (241 ± 39); after PDGF stimulation both
fractions (10k and 100k) had two mode sizes: 44 ± 6 nm
and 225 ± 48 nm (Figure 1A), suggesting that PDGF stimu-
lated the secretion of smaller EVs.ed after 10k and 100k g ultracentrifugation. A: NanoSight
GF-EVs; B: diagram of EV quantity per single ASC after stimulation with
rifugation of conditioned media. In selected experiments ASCs were
ith PDGF (+ab + PDGF), (mean ± SEM, * - p < 0,05, n = 12); C: diagram
media of ASC (mean ± SEM, * - p < 0,05, n = 10); D: representative
EVs and in ASCs (10 μg of proteins/well; image of ponseau red
structures after HMEC stimulation with different EV fractions; as control
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after DNA extraction and analysis using spectropho-
tometry (NanoDrop) and by agarose gel electrophoresis
(Bioanalyser). EVs were stained with PKH26, which
labelled membrane phospholipids, indicating that parti-
cles detected both in 10K and 100K fractions were not
protein aggregates (Figure 2A). Both 10k and 100k
fractions expressed several mesenchymal surface markers
characteristic of cell origin as seen by GUAVA FACS
analysis. EVs expressed mesenchymal surface markers
(CD73, CD29, CD90, CD105, CD44), endothelial markers
(CD105, CD31), and marker of exosomes (CD63, CD81).
The expression did not change in different fractions of
EVs or EVs obtained after stimulation with PDGF with the
exception of CD81 expression, which was increased in
100 k fraction of PDGF-EVs in respect to b-EVs (Table 1).
Similar results were obtained by FACS analysis performed
on vesicles pre-absorbed on beads (not shown).
In basal conditions ASCs produced about 1×105 ± 1×103
EVs (b-EVs) per cell. As shown in Figure 1C, the amount
of PDGF-EVs was significantly increased in respect to
b-EVs whereas other growth factors such as FGF orFigure 2 EV effect on HMEC. A: representative confocal microphotograph
are blue) incubated with EVs for 30 minutes, 3 and 6 hours; four experimen
response to b-EV or PDGF-EV addition; 10% FBS was used as positive contr
diagram of HMEC invasiveness into Matrigel after b-EV or PDGF-EV stimulat
inhibitor Batimastat (mean ± SEM, * p < 0.05 vs. non-stimulated HMEC, # p < 0
n = 12); D: representative zymography of b-EVs and PDGF-EVs; intensity of MM
conditioned media of HMEC 24 hours after b-EV or PDGF-EV addition; proMM
(62 kD) are present; the intensity (itn.) of bands is indicated.VEGF did not increase EV secretion. Blocking anti-
bodies anti PDGFR α/β inhibited the enhanced secre-
tion of EVs by ASCs (Figure 1B). Therefore we focused
on PDGF stimulation of ASCs. By NanoSight analysis
the fraction of EVs increased after PDGF stimulation
was the 100k fraction (Figure 1C).
The expression of CD81, CD63 and Alix was con-
firmed by Western blot analysis (Figure 1D).
The 10k and 100k fractions did not show significant
difference in the ability to induce in vitro angiogenesis
(Figure 1E). Taken together these experiments indicated
that 10k and 100k fractions did not qualitatively and
functionally differ. However, the amount of EVs obtained
in the 10k fraction was 100 times lower than in 100k
fraction (Figure 1C). Therefore we decided to use total
100k fraction for further experiments.
Protein composition of ASC-derived EVs
The protein array analysis for 507 secreted proteins
showed difference in protein content of b-EVs and PDGF-
EVs (Table 2). After PDGF stimulation EVs expressed
members of interleukin 6 group of cytokines (OSM, LIF)y of 100k total EVs labelled with PKH26 dye (red), and HMEC (nuclei
ts were done with similar results; B: diagram of HMEC proliferation in
ol (mean ± SEM, * p < 0.05 vs. non-stimulated control HMEC, n = 6); C:
ion in presence (red column) or absence (blue column) of the MMPs
.05 stimulation in the presence of Batimastat vs. absence of Batimastat,
P2 and MMP9 bands are indicated; E: representative zymography of
P-9 (92 kD), active MMP-9 (82 kD), proMMP-2 (72 kD) and active MMP-2
Table 1 Marker expression on EV surface, shown by GUAVA FACS analysis
b-EVs PDGF-EVs
10 k 100 k tot.100 k 10 k 100 k tot.100 k
CD73 69,5 (±9,3) 69,5 (±8,7) 72,5 (±6,4) 72 (±9,6) 71 (±5,3) 68,5 (±4,9)
CD105 37 (±11,6) 34 (±10,0) 42,5 (±7,8) 35,5 (±8,5) 37,5 (±6,6) 50,5 (±3,5)
CD90 73,5 (±5,4) 66 (±5,3) 74,5 (±0,7) 76 (±5,0) 75,5 (±6,7) 81,5 (±2,1)
CD44 55,5 (±10,7) 53 (±7,7) 48 (±8,5) 57 (±12,8) 61,5 (±14,4) 53 (±22,6)
CD29 66 (±13,4) 59 (±8,0) 62 (±1,4) 70 (±13,9) 63,5 (±10,7) 63 (±17,0)
CD31 65,5 (±15,2) 61 (±11,8) 66,5 (±3,5) 65 (±11,6) 65,5 (±10,6) 63 (±13,1)
CD81 22 (±11,1) 8,65 (±6,1) 16 (±1,4) 23 (±11,2) 21,5 (±10,5) 22,5 (±19,1)
CD63 6,5 (±5,6) 7,5 (±5,6) 14 (±5,4) 9,25 (±5,7) 9,25 (±5,8) 25 (±7,3)
Mean ± SEM, in bold - p < 0,05, n = 4.
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c-kit, SCF (Figure 2B). For what concern angiogenesis,
both b-EVs and PDGF-EVs contained pro- (Artemin [22],
Axl [23,24], MFG-E8 [25], Osteoprotegerin [26,27]), and
anti-angiogenic factors (IGFBP-7 [28], Pentraxin3 [29],
sFRP-4 [30], SPARC [31-33], Thrombospondin-1 [34],
TIMP-2 [35]).
B-EVs at variance from PDGF-EVs contained pro-
angiogenic factors (Angiopoietin-like Factor [36], APJ
[37], IL-1α [38], MIP 2 [39]), anti-angiogenic factors
Angiostatin and Endostatin [40], and polyvalent regu-
lators Activin C [41], GCSF [42,43].
PDGF-EVs in contrast with b-EVs contained pro-
angiogenic factors (Thrombopoietin [44], various types
of MMPs [45], OSM [46]) and anti-angiogenic factors
(6Ckine [47], TIMP-1 [48], LIF [49,50]).
B-EVs as well as PDGF-EVs did not contain PDGF; this
was confirmed by Western blot analysis (not shown).
ASC-derived EVs are internalized by HMEC, stimulate their
proliferation and promote invasion
For all in vitro experiments we decided to use concen-
tration of EVs equal to their concentration in ASC con-
ditioned media. When ASCs achieved confluence the
concentration was 1 × 1011 ± 1× 103 EVs/ml that corre-
sponded 1 × 105 ± 1× 102 per cell.
ASC-derived EVs entered HMEC after 30-minute incu-
bation (Figure 2A). No difference in b-EV and PDGF-EV
uptake was observed. However, PDGF-EVs significantly
stimulated HMEC proliferation in respect to b-EVs
(Figure 2B).
We also examined the effect of EVs on HMEC inva-
sion. 10% of FBS was used as attractant. EVs significantly
increased the invasiveness of HMEC (Figure 2C, blue
columns). Since EVs contained various types of MMPs,
we performed zymography analysis to investigate the
mechanisms of the invasion-promoting activity of EVs.
Both b-EVs and PDGF-EVs carried pro- and activeforms of MMP-2 and MMP-9, but PDGF-EVs con-
tained significantly more proMMP2 and actMMP2
(Figure 2D, Additional file 1: Figure S1C). Moreover,
24 hours after EV addition, the expression of MMPs in
HMEC conditioned media was significantly increased
(Figure 2E, Additional file 1: Figure S1D). Since MMPs
were absent in HMEC conditioned media 4 hours after
EV addition (not shown), this result cannot be accounted
to the amount of MMPs present in EVs, but rather to
an induction of MMPs synthesis by EV-stimulated
HMEC.
Invasiveness of HMEC was partially suppressed by the
addition of the MMP inhibitor Batimastat (Figure 2C,
red columns) confirming the role of MMPs in EV-
enhanced invasiveness of HMEC.
ASC-derived EVs stimulated in vitro formation of vessel-
like structures by HMEC
EVs promoted significantly formation of vessel-like by
HMEC in a dose-dependent manner, and their maximum
activity (1 × 1011 EVs/ml) was comparable with that of
VEGF (Figure 3).
The difference between stimulated HMEC and non-
stimulated was evident after 48 hours, when vessel-like
structures in control samples were disassembled. When
compared, the in vitro angiogenic activity of PDGF-EVs
was significantly enhanced in respect to b-EVs (Figure 3G).
To evaluate the contribution of EVs in angiogenesis
we deprived the conditioned medium of EVs by ultra-
centrifugation and the effective deprivation was checked
by NanoSight.
The difference between HMEC stimulated with EVs or
EV-free supernatant was evident after 48 hours. After
48 h in EV-free supernatant samples no vessel-like struc-
tures were present, but HMEC proliferated and formed
a monolayer. At 48 h EV-stimulated HMEC showed
stable vessel-like structures, whereas boiling abrogated
EV effects (Additional file 1: Figure S1B).
Table 2 EV proteins that were consistently detected by
protein assay
b-EVs: PDGF-EVs:
APRIL APRIL
Artemin* Artemin*
Axl* Axl*
B7-1/CD80 B7-1/CD80
BAFF R/TNFRSF13C BAFF R/TNFRSF13C
EDA-A2 EDA-A2
IGFBP-rp1/IGFBP-7^ IGFBP-rp1/IGFBP-7^
Kremen-2 Kremen-2
LRP-6 LRP-6
MFG-E8* MFG-E8*
MMP-20 MMP-20
Osteoprotegerin/TNFRSF11B* Osteoprotegerin/TNFRSF11B*
Pentraxin3/TSG-14^ Pentraxin3/TSG-14^
sFRP-4^ sFRP-4^
SPARC^ SPARC^
Thrombospondin-1^ Thrombospondin-1^
TIMP-2^ TIMP-2^
Activin C 6Ckine^
Angiopoietin-like Factor* IL-17RD
Angiostatin^ IL-20 R alpha
APJ* Inhibin A
AR (Amphiregulin) I-TAC/CXCL11
CCL14/HCC-1 / HCC-3 Latent TGF-beta bp1
CCL28/VIC Lck
CV-2/Crossveinless-2 LIF^
Endostatin^ MCP-3
GCSF MMP-10*
Glypican 3 MMP-11/Stromelysin-3
IL-1 alpha* MMP-14
MIP 2* MMP-9*
OSM*
SCF*
SCF R/c-kit/CD117*
sgp130
TGF-beta 5
Thrombopoietin (TPO)*
TIMP-1^
TRAIL R4/TNFRSF10D
*Indicate pro-angiogenic proteins; ^indicate anti-angiogenic proteins.
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when ASCs were placed in upper chamber of transwell:
co-culture with ASCs stimulated proliferation of HMEC
rather vessel formation.ASC-derived EVs enhance angiogenic capacity of HMEC
in vivo
Previously HMEC were stimulated with EVs (1 × 1010
EVs per 1 × 106 HMEC) during 3 hours at 37°C, than the
cells were mixed with Matrigel (1 × 106 cells/500 μl) and
subcutaneously injected into SCID mice. Ten days after
injection, the Matrigel plugs were excised, fixed, and
embedded. As shown in Figure 4, angiogenesis was
significantly enhanced by HMEC pre-stimulation with
EVs (Figure 4A, B, D). PDGF-EVs significantly increased
angiogenesis in respect to b-EVs (Figure 4C and D).
c-kit/SCF signaling pathway play an important role in
angiogenic activity of PDGF-EVs
Since PDGF-EVs carry c-kit and SCF (Figure 5A) we
evaluated their role in PDGF-EV-induced angiogenesis.
For this purpose we incubated PDGF-EVs with neutraliz-
ing antibodies anti-c-kit or anti-SCF (at concentration
1 μg per 1 × 1011 EVs), then we washed PDGF-EVs with
DMEM by ultracentrifugation at 100k g for 1 hour at
4°C. For controls we have used isotopic irrelevant anti-
body as well as anti-c-kit and anti-SCF antibodies incu-
bated with HMEC in the absence of EVs. Incubation
HMEC with PDGF-EVs changed the expression of c-kit
and SCF in the cells (Figure 5A). As HMEC express c-kit
and SCF, blocking antibodies interacted with endogenous
c-kit and SCF and therefore abrogated their pro-angiogenic
activity. Blockade of SCF or c-kit did not change action of
b-EVs, but the enhanced pro-angiogenic activity of PDGF-
EVs was significantly inhibited (Figure 5B), but not
completely abrogated suggesting the presence of other
pro-angiogenic factors.
Conclusions
The results of the present study demonstrated that EVs
released from ASCs stimulated in vitro and in vivo
angiogenesis and that PDGF enhanced EV release and
their angiogenic properties. Previous studies demon-
strated that EVs produced by bone-marrow derived
MSCs contribute to tissue remodeling after injury [12].
In the present study we focused on the angiogenic
potential of EVs derived from ASCs that may represent a
suitable source of adult stem cells for regenerative medi-
cine. We found that ASC-EVs contain a set of angiogenic
factors such as MFG-E8, ANGPTL1, Thrombopoietin.
Moreover, EVs were found to carry MMPs that play an
important role in angiogenesis by facilitating endothelial
cell migration and by promoting activation of angiogenic
growth factors and other signaling molecules [45]. We
evaluated whether ASC stimulation with growth factors
involved in angiogenesis might modify the angiogenic
activity of EVs. PDGF, but not VEGF or FGF, was found to
enhance EV secretion and to change their content of pro-
angiogenic mediators resulting in an enhanced angiogenic
Figure 3 EVs enhance the angiogenic capacity of HMEC in vitro. Vessel-like structures formation by HMEC with or without EV stimulation.
A: negative control DMEM FBS-free; B: positive control 20 ng/ml VEGF; C: b-EVs 1 × 105 EVs/ml; D: b-EVs 1 × 1011 EVs/ml; E: b-EVs 1 × 1015 EVs/ml;
F: PDGF-EVs 1 × 1011 EVs/ml; G: quantitative analysis of vessel-like structures formation in response to varies doses of b-EVs and to PDGF-EVs
(mean ± SEM, * - p < 0,05 vs. “-control”, # - p < 0,05 vs. “b-EVs, 30 μg/ml”, n = 8).
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zation after injury [17,18]. ASCs express high levels of
PDGFRβ that are fundamental in the proliferation,
adhesion and migration to the sites of angiogenesis
[20,21,51,52]. ASCs recruited at the sites of injury may
therefore contribute to angiogenesis through the release
of EVs. Moreover, the finding that the protein compos-
ition of EVs was modulated by cell stimulation indicates
that packing of mediators within EVs is a regulated process.
Indeed, PDGF stimulated the secretion of ASC-EVs with
de novo expression of pro-angiogenic molecules such as
c-KIT and SCF, and with the absence of anti-angiogenic
molecules such as Angiostatin and Endostatin. C-kit is a
tyrosine kinase receptor expressed by progenitor cells
differentiating into blood or vascular endothelial cells [53]
and plays an important role in the amplification and
mobilization of progenitor cells. Therefore, EVs carrying
C-kit might recruit endothelial progenitor cells at the site
of tissue remodeling. The c-kit ligand SCF promotes sur-
vival, migration, and vessel-like formation of endothelialcells and recruitment of MSCs [53,54]. The observation
that blockade of c-kit and SCF significantly reduced the an-
giogenic potential of PDGF-EVs suggested a contribution
of these factors in EV-induced angiogenesis.
In conclusion, the results of the present study demon-
strate that PDGF potentiate the pro-angiogenic activity
of EVs released from ASCs by enhancing their produc-
tion and modulating their content of pro-angiogenic and
anti-angiogenic factors.
Methods
Cell cultures
Human ASCs were obtained from Lonza (Basel,
Switzerland), cultured in complete MSCGM™ Mesenchy-
mal Stem Cell Growth Medium (Lonza) containing, 1%
antibiotic–antimycotic (HyClone) at 37°C in 5% CO2 incu-
bator. When homogeneous monolayer with typical fibro-
blast morphology was obtained, ASCs were passaged
using trypsin solution (Sigma, St. Louis, MO, USA). For
the experiments, cells of the 4–6 passages were used. At
Figure 4 b-EVs and PDGF-EVs stimulate angiogenesis in vivo. A-C: representative Matrigel sections stained by trichrome method.
Erythrocyte-contained vessels are indicated by arrows; A: spontaneous vessel formation in control Matrigel plug, containing non-stimulated HMEC;
B: vessel formation in Matrigel plug, containing HMEC stimulated with b-EVs; C: vessel formation in Matrigel plug, containing HMEC stimulated
with PDGF-EVs; D: quantitative analysis of vessel formation counted in 10 sections of Matrigel at ×20 magnification per each experimental condition;
(mean ± SEM, * - p < 0,05 vs. “-control”, # - p < 0,05 vs. “b-EVs”, n = 5).
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evaluation of mesenchymal properties were performed as
previously described [55].
HMECs were purchased from Lonza (Basel, Switzerland)
and were cultured in EBM-2 growth medium (Lonza)
supplemented with a cocktail of angiogenic factors
(SingleQuots, Lonza) according to the instructions of
the manufacturer.
Isolation and characterization of ASC-EVs
For collection of EVs from supernatants ASCs were cul-
tured one day without FBS. In selected experiments
20 ng/ml PDGF, VEGF or FGF were added one day after
deprivation. EVs were obtained from supernatants of
ASCs after 2 days culture in DMEM with or without
additional factors. After centrifugation at 3k g for
30 minutes to remove debris, cell-free supernatants
were submitted to differential ultracentrifugation at
10k and 100k g (Beckman Coulter Optima L-90Kultracentrifuge; Beckman Coulter, Fullerton, CA) for
3 hours at 4°C. In selected experiments the 10k g centrifu-
gation was omitted. EVs were used freshly or stored at
−80°C after resuspension in DMEM supplied with 5% of
DMSO. For cellular experiments frozen EVs were previ-
ously washed and pelleted by 100k g ultracentrifugation
to remove DMSO. No difference in biological activity
was observed between fresh and stored EVs. The pro-
tein content of MVs was quantified by Bradford method
(BioRad, Hercules, CA, USA). Endotoxin contamination
of MVs was excluded by Limulus test (Charles River
Laboratories, Inc., Wilmington, MA, USA).
Analysis of size distribution of EVs was performed
using NanoSight LM10 (NanoSight Ltd, Minton Park
UK). Using a laser light source the particles in the sample
are illuminated and the scattered light is captured by the
camera and displayed on the connected PC running
Nanoparticle Tracking Analysis (NTA). Using NTA, the
particles are automatically tracked and sized based on
Figure 5 Effect of anti-c-kit or anti-SCF blocking antibodies on in vitro vessel-like structure formation by HMEC. A: representative
western blot analysis of b-EVs, PDGF-EVs and HMEC after stimulation with these EVs; B: quantitative analysis of vessel-like structures formation in
response to EVs at presence of blocking antibodies anti-c-kit or anti-SCF (mean ± SEM, # - p < 0,05 vs. “control”, * - p < 0,05 vs. “PDGF-EVs”, n = 7).
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sults are displayed as a frequency size distribution graph
and output to a spreadsheet.
To trace EVs by fluorescent microscopy, EVs were
labeled with the red fluorescent aliphatic chromophore
intercalating into lipid bilayers PKH26 dye (Sigma-
Aldrich). After labeling, EVs were washed and ultracen-
trifuged at 100k g for 1 hour at 4°C. EV pellets were
suspended in DMEM. Confocal microscopy was per-
formed using a Zeiss confocal microscope, model LSM
5 PASCAL (Jena, Germany).
Characterization of ASCs and ASC-derived EVs
Fluorescence-activated cell sorting (FACS) analysis of
ASC-derived EVs was performed as described [56]
using the following FITC- or PE-conjugated antibodies
(Abs) directed to CD29, CD105, CD73, CD90 (Dako
Cytomation, Copenhagen, Denmark), CD31 (Becton
Dickinson); CD63, CD81 (Miltenyi Biotec, Bergisch
Gladbach, Germany). FITC or PE mouse non-immune
isotypic IgG (Dako Cytomation) was used as control.FACS analysis of ASC-derived EVs was performed with
Guava easyCyte™ Flow Cytometer (Millipore, Germany)
[57,58]. To perform FACS analysis of EVs, in suspension
of EVs (in quantity 250 particles per 1 μl, 100 μl) were
added FITC- or PE-conjugated antibodies (mentioned
previously) for 15 minutes at 4°C. Then, volume was in-
creased with FACS flow till 500 μl. Expression of surface
markers was measured according to the manufacturer’s
instructions (Biocytex, France). We also performed FACS
analysis after absorption on beads. Briefly, EVs (10 μg)
were incubated for 30 minutes to overnight on ice with
5 μl of latex beads (Aldeyde/sulphate LATEX 4MM, invi-
trogen) then washed in PBS supplemented with 100 mM
glycine and incubated for 30 minutes with the antibodies
described above.
DNA detection
DNA quantification was done by using Nanodrop
Spectrophotometer (ND-1000, Thermo Fischer Scientific,
Wilmington DE, USA), along with determining absorb-
ance ratio at 260/280 nm for evaluating the quality of
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using Agilent 2100 Bioanalyser protocol and the Nano-
Chip or PicoChip. No EV DNA was detected.
Cell proliferation assays
HMEC were seeded at 8000 cells/well into 96-well plates
in DMEM deprived of FBS. B-EVs or PDGF-EVs were
added (1 × 107 EVs/×103 cells) for 3 days. DNA synthesis
was detected as incorporation of 5-bromo-2-deoxyuri-
dine (BrdU) into the cellular DNA using an ELISA kit
(Roche Applied Science, Mannheim, Germany), follow-
ing the manufacturer’s instructions.
Cell invasion assay
The effect of EVs on HMEC invasion was detected by
the Transwell assay (COSTAR transwell, Corning Incorpo-
rated, MA, USA). HMEC were resuspended in DMEM
(serum free) or in DMEM with b-EVs or PDGF-EVs
(1 × 1011 EVs/ml) and were seeded into the upper com-
partment of an invasion chamber (30 × 103 cells per
well) containing a polycarbonate membrane with an
8 μm pore size which was coated with a layer of extra-
cellular matrix (ECM; MatrigelTM, Becton Dickinson,
NJ, USA). FBS (10%) was used as the attractant and
added to the lower well. As a positive control, HMEC
were stimulated with 10% FBS. After 48 h of incubation,
the invasive cells migrated through the ECM layer to
the complete medium in the lower compartment. The
invasive cells were stained with Mayer and the number
of invaded cells was counted. Every experiment was
repeated 12 times, statistical analysis was applied among
the groups.
In some experiments EVs were incubated for 1 hour
at 37°C with Batimastat (1 μg/1 × 1010 of EVs) a MMP
inhibitor and were washed by ultracentrifugation to in-
hibit EV-associated MMPs of before addition to HMEC.
Gelatin zymography
Zymography was performed using “Ready Zymogram
Precast Gel” (Biorad) (10%) gels copolymerized with
1 mg/ml gelatin. b-EVs and PDGF-EVs were loaded
3 μg of proteins per well. In zymogram analysis of condi-
tioned media, media were collected from equal number of
HMEC stimulated with EVs (1 × 1011 particle/ml). As pro-
tein concentration between different samples of media
was identical, loading volume was 30 μl per well for all
samples. Samples were mixed with Laemmli’s buffer
without β-mercaptoethanol and incubated at room
temperature for 10 min. After electrophoresis, gels
were washed twice for 30 min in 2.5% Triton X-100 at
room temperature, incubated overnight in collagenase
buffer [50 mM Tris–HCl (pH7.5), 10 mM CaCl2, and
150 mM NaCl] at 37°C, and then stained with Coomas-
sie brilliant blue R-250.Protein array
Purified EVs were lyzed in 1 ml of 2× Cell Lysis Buffer
(RayBiotech, Inc, GA), and aliquots (1 mg of EV protein)
were used for “RayBio Biotin Label-based Human Anti-
body Array I” (RayBiotech, Inc, GA) that was performed
according to the manufacturer instructions. The biotin-
conjugated antibodies on each membrane served as posi-
tive controls. The array image was captured and analyzed
by the ChemiDoc™ XRS + System (Bio-Rad). The array
provides detection of 507 secreted proteins. The analysis
was repeated with three different samples of b-EVs and
PDGF-EVs. Only proteins detected in all three experi-
ments were mentioned as consistently detected.
Immunoblotting
Protein samples were separated by 4% to 15% gradient so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis
and subjected to immunoblotting with antibodies to c-kit,
SCF, PDGF (Abcam, UK), CD63, CD81, Alix (Santa Cruz).
The protein bands were visualized with an enhanced
chemiluminescence (ECL) detection kit and ChemiDoc™
XRS + System (BioRad). Cell and EV lysates were loaded
at concentration of 10 μg/well. As no protein can be used
as housekeeping control for concomitant detection of cells
and EVs, we controlled protein transfer by ponseau stain-
ing (see Additional file 1: Figure S1A).
Vessel-like formation assay
HMECs (30 × 103 cells per well) were seeded onto
Matrigel-coated wells in a 24-well plate and cultured in
DMEM medium without FBS in the presence of differ-
ent types of EVs in concentration 1 × 105, 1 × 1011, 1 ×
1015 EVs/ml. As a positive control VEGF (20 ng/ml) was
used. Non-immune IgG or blocking antibody (1 μg/ml)
were added when required. In experiments with EVs and
blocking antibodies, EVs were washed after binding to
remove unbounded antibodies. After incubation for
24 h, phase-contrast images (magnification, ×100) were
recorded and the total length of the network structures
was measured using MicroImage analysis system (Casti
Imaging, Venice, Italy) [56]. The total length per field
was calculated in five random fields and expressed as a
ratio to the respective control.
In vivo angiogenesis assay
Animal studies were conducted in accordance with the
National Institute of Health Guide for the Care and Use
of Laboratory Animals. The protocol was approved by
the Committee on the Bioethics of the University of
Torino (Permit Number: 1.3.10).
Angiogenesis was assayed by measuring the growth of
blood vessels from subcutaneous tissue into a solid gel of
basement membrane, as previously described [6,7]. Firstly,
HMEC (1 × 106 cells/injection) were incubated with b-EVs
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3 hours. Then, male severe combined immunodeficiency
(SCID) mice (8 wk old) were injected subcutaneously with
0.5 ml of ice-cold BD Matrigel Matrix Growth Factor
Reduced (BD Biosciences, Franklin Lakes, NJ), which
had been mixed with pre-stimulated HMEC. Equivalent
quantity of non-stimulated HMEC was used as a nega-
tive control. The Matrigel plugs were excised after
10 days and fixed in 4% paraformaldehyde for 4 h.
Matrigel-containing paraffin sections (5–8 μm thick)
were stained by trichrome stain method [59]. The vessel
lumen area (mean size per square millimeter) and quan-
tity of erythrocyte-containing vessels were determined
using computerized image analysis software MicroIm-
age analysis system (Casti Imaging).Statistical analysis
All experiments were performed at least 6 times. Data
was assessed for normality of distribution using the
Kolmogorov-Smirnov test. Statistical analysis was per-
formed using SigmaPlot11.0 Software. Differences be-
tween treatment and control groups were then analyzed
using Student t-test. Data are expressed as mean ± SEM.
We considered differences to be significant when
p < 0.05.Additional file
Additional file 1: Figure S1. A: representative image of ponseau red
staining of western blot membrane with EVs and ASCs protein samples;
B: quantitative analysis of vessel-like structures formation in response to
co-culture with ASCs in transwell, EV-free supernatant (SuperNat), native
and denatured (by boiling) EVs (mean±SEM, # - p<0,05 vs. “control”,
^ - p<0,05 vs. “b-EVs”, * - p<0,05 vs. “PDGF-EVs”, n=5); C: comparison of
MMP expression in b-EVs and PDGF-EVs, performed by zymography and
analyzed using densitometry (mean±SEM, * - p<0,05 vs. “b-EVs”, n=6);
D: comparison of MMP expression in conditioned media of HMEC,
stimulated with b-EVs or PDGF-EVs (mean±SEM, * - p<0,05 vs. “control”, n=7).Abbreviations
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